Latest ImmunityBio News & Updates

See the latest news and media coverage for ImmunityBio. We track all announcements, press releases, and industry mentions in real time, all in one place.

ImmunityBio

Biotechnology company developing immunotherapies for cancer and infectious diseases

immunitybio.com

Headquarters: San Diego, United States
Founded year: 2014
Company type: Public company
Number of employees: 600–1,000
Industry: Pharmaceuticals

Last updated Today

Latest news about ImmunityBio

In short: ImmunityBio reported record quarterly revenue and expanded the global footprint of its immunotherapy drug ANKTIVA with new approvals.

Company announcements

August 10 ImmunityBio

ImmunityBio appoints Dr Jim Yong Kim as Vice Chairman

He will lead the new Office of the Executive Chairman, focusing on international partnerships and global access initiatives.

August 4 ImmunityBio

ImmunityBio reports record Q2 product revenue of $50.7 million

First-half revenue rose 121% to $94.8 million; cash totals $357.4 million; FDA accepted sBLA for ANKTIVA plus BCG.

July 29 ImmunityBio

ImmunityBio receives UAE marketing authorization for ANKTIVA

The authorization covers BCG-unresponsive NMIBC and metastatic NSCLC, expanding to 34 countries.

June 1 ImmunityBio

ImmunityBio presents new data across lung and bladder cancers

The data includes Phase 3 trial results in advanced NSCLC and a comparative analysis in BCG-unresponsive NMIBC.

Media coverage

Today MSN

SLS, IBRX stocks in focus: Analyst says Moderna-Merck cancer vaccine success bodes well for oncology

Moderna soared 177% Wednesday, while Merck gained 13% and the rally spread to BioNTech, Arcturus, Tempus AI and Novavax.

August 5 Yahoo Finance

IBRX Q2 Earnings & Sales Beat Estimates on Strong Anktiva Uptake

ImmunityBio beat Q2 earnings and revenue estimates as record Anktiva sales and continued adoption...

August 5 Yahoo Finance

Pfizer, Merck, Amgen Double Down On Cancer And Send Takeover Buzz Around SLS And IBRX Into Overdrive

IBRX and SLS align with Big Pharma’s cancer push, fueling retail partnership and buyout speculation.

August 4 Barron's

ImmunityBio Inc.

ImmunityBio Inc. stock grades by Barron's. View IBRX fundamental and sentiment analysis powered by MarketGrader.

Never miss news about ImmunityBio

Track ImmunityBio and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

ImmunityBio competitors & trending companies

Browse news for competitors to ImmunityBio and other trending companies.